Terms ending in 2039

The Institut Pasteur

Every in-force patent on The Institut Pasteur's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.

Patent	Title	Holder	Status	Expires	Confidence
US 10,435,676	Variants of Terminal Deoxynucleotidyl Transferase and Uses Thereof Institut Pasteur and National Center for Scientific Research (CNRS) In force Term ends Jan 8, 2039 · High confidence	Institut Pasteur and National Center for Scientific Research (CNRS)	In force	Term ends Jan 8, 2039	High confidence
US 10,752,887	Variants of Terminal Deoxynucleotidyl Transferase and Uses Thereof Dna Script In force Term ends Jan 8, 2039 · High confidence	Dna Script	In force	Term ends Jan 8, 2039	High confidence
US 11,208,637	Variants of Terminal Deoxynucleotidyl Transferase and Uses Thereof Institut Pasteur and National Center for Scientific Research (CNRS) In force Term ends Jan 8, 2039 · High confidence	Institut Pasteur and National Center for Scientific Research (CNRS)	In force	Term ends Jan 8, 2039	High confidence
US 12,286,652	Variants of Terminal Deoxynucleotidyl Transferase and Uses Thereof Dna Script In force Ends no later than Jan 8, 2039 · Medium confidence	Dna Script	In force	Ends no later than Jan 8, 2039	Medium confidence
US 12,168,805	Methods and Reagents for Detecting Piperaquine-Resistant Plasmodium Falciparum Malaria Institut Pasteur, Institut Pasteur du Cambodge and Centre National de la Recherche Scientifique In force Term ends Feb 26, 2039 · High confidence	Institut Pasteur, Institut Pasteur du Cambodge and Centre National de la Recherche Scientifique	In force	Term ends Feb 26, 2039	High confidence
US 11,872,276	Zika Virus Chimeric Polyepitope Comprising Non-Structural Proteins and Its Use in an Immunogenic Composition Institut Pasteur In force Term ends Mar 5, 2039 · Medium confidence	Institut Pasteur	In force	Term ends Mar 5, 2039	Medium confidence
US 11,723,968	Stabilized Recombinant Hantaviral Spike Proteins Comprising Mutations in GC Fundación Ciencia Para la Vida and Institut Pasteur In force Term ends Mar 13, 2039 · High confidence	Fundación Ciencia Para la Vida and Institut Pasteur	In force	Term ends Mar 13, 2039	High confidence
US 12,071,638	Variants of Terminal Deoxynucleotidyl Transferase and Uses Thereof Dna Script SAS In force Ends no later than May 6, 2039 · Medium confidence	Dna Script SAS	In force	Ends no later than May 6, 2039	Medium confidence
US 12,521,428	Malaria pre-erythrocytic antigens as a fusion polypeptide and their use in the elicitation of a protective immune response in a host Institut Pasteur In force Term ends May 23, 2039 · High confidence	Institut Pasteur	In force	Term ends May 23, 2039	High confidence
US 12,059,457	Immunogenic Product Comprising IL-4 And/Or IL-13 for Treating Disorders Associated with Aberrant IL-4 And/Or Il 13 Expression or Activity Neovacs, Inserm (Institut National de la Santé et de la Recherche Médicale) and Institut Pasteur In force Term ends May 29, 2039 · High confidence	Neovacs, Inserm (Institut National de la Santé et de la Recherche Médicale) and Institut Pasteur	In force	Term ends May 29, 2039	High confidence
2 more term ends in 2039 · Pro

10 of 12 patents shown. Soonest term end first, then patent number.

Pro members see all 12.

Upgrade to Pro

9 of these are in force and held by The Institut Pasteur.

Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.